View detailed drug regimens for the treatment of brain cancer, including treatments such as temozolomide, carboplatin, and methotrexate.
More patients living with metastatic breast cancer reportedly would be willing to participate in clinical trials if some changes were made.
[Lung Cancer: Targets and Therapy] Data from two phase 2 studies, NP28673 and NP28761, suggest that patients with previously treated ALK-positive NSCLC experienced rapid time to systemic response and time to CNS response with alectinib.
ONA talked with Adam M. Brufsky, MD, on promising studies from ESMO Congress 2019 on the use of immunotherapy in HR+, HER2– and metastatic triple-negative breast cancers.
Researchers sought to determine if presence of comorbidities influences the underrepresentation of African American patients with acute myeloid leukemia in clinical trials.